Merck & Co., Inc. (MRK): Shareholders' Equity
$52.66B
As of 2025-12-31
$41.98B
As of 2026-06-30
+4.6%
3-year compound annual growth
+15.7%
5-year compound annual growth
+1.6%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $52.66B | +13.6% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $46.37B | +23.2% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $37.63B | -18.3% | 2026-02-24, Balance as of period end |
| 2022-12-31 | $46.06B | +20.4% | 2025-02-25, Balance as of period end |
| 2021-12-31 | $38.26B | +50.6% | 2024-02-26, Balance as of period end |
| 2020-12-31 | $25.40B | -2.3% | 2023-02-24, Balance as of period end |
| 2019-12-31 | $26.00B | -3.3% | 2022-02-25, Balance as of period end |
| 2018-12-31 | $26.88B | -22.2% | 2021-02-25, Balance as of period end |
| 2017-12-31 | $34.57B | -14.2% | 2020-02-26, Balance as of period end |
| 2016-12-31 | $40.31B | -10.0% | 2019-02-27, Balance as of period end |
| 2015-12-31 | $44.77B | -8.2% | 2018-02-27, Balance as of period end |
| 2014-12-31 | $48.79B | -6.8% | 2017-02-28, Balance as of period end |
| 2013-12-31 | $52.33B | -5.7% | 2016-02-26, Balance as of period end |
| 2012-12-31 | $55.46B | -2.6% | 2015-02-27, Balance as of period end |
| 2011-12-31 | $56.94B | +0.2% | 2014-02-27, Balance as of period end |
| 2010-12-31 | $56.80B | -7.6% | 2013-02-28, Balance as of period end |
| 2009-12-31 | $61.48B | +190.5% | 2012-02-28, Balance as of period end |
| 2008-12-31 | $21.17B | +2.8% | 2011-02-28, Balance as of period end |
| 2007-12-31 | $20.59B | n/a | 2010-03-01, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | 2025-12-31 | $52.66B | +13.6% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $26.54B | +85.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $86.78B | -1.9% |
| AbbVie Inc. (ABBV) | 2025-12-31 | -$3.27B | n/m |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $18.47B | +13.1% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $81.54B | +14.1% |
| Abbott Laboratories (ABT) | 2025-12-31 | $52.13B | +9.4% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $7.91B | +47.1% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $31.26B | +6.5% |
Compare MRK, LLY, PFE, ABBV side by side · Screen every company in Pharmaceutical Preparations ↗